Clinical Trial Update: AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating AMG 162 for preventing bone loss in women undergoing aromatase inhibitor therapy for non-metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Low Bone Mineral Density
• Osteopenia

Drugs mentioned

• AMG 162

Snippet

Sponsor: Amgen | Conditions: Breast Cancer, Low Bone Mineral Density | Phase 3 | Status: COMPLETED | Results posted: 2010-01-26